Protagonist Therapeutics, Inc PTGX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-08-11
Protagonist Therapeutics, Inc statistics & valuation
Market cap$7.8B
P / B12.8×
P / FCF139.8×
Net margin-282.8%
Return on equity-21.2%
FCF margin121.9%
Return on capital-25.4%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -343.6% | 58.2% | -156.1% | -494.2% | -460.0% | -225.4% | -34857.6% | -136.7% | -188.9% | — |
| Net margin | -282.8% | 63.3% | -131.6% | -479.3% | -458.9% | -231.1% | -33414.3% | -125.9% | -184.2% | — |
| FCF margin | 121.9% | 42.1% | -118.1% | -409.8% | -398.3% | -254.8% | -18395.7% | -163.1% | 16.0% | — |
| Return on assets | -19.5% | 37.0% | -22.1% | -51.4% | -36.1% | -20.4% | -49.8% | -27.9% | -22.6% | -39.6% |
| Return on equity | -21.2% | 40.8% | -23.5% | -59.1% | -41.8% | -23.7% | -96.5% | -34.6% | -30.6% | -42.5% |
| Debt / equity | — | — | — | — | — | — | 0.12× | — | — | — |
| Current ratio | 12.71 | 12.48 | 16.71 | 7.80 | 7.74 | 7.84 | 4.10 | 5.26 | 3.55 | 12.94 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.